Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6

Translational Psychiatry

Volumn 5, Issue 9, 2015, Pages

  Tsilioni, I ^a   Taliou, A ^b   Francis, K ^b   Theoharides, T C ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; INTERLEUKIN 31; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 9; LUTEOLIN; NEUROTENSIN; QUERCETIN; RUTOSIDE; TUMOR NECROSIS FACTOR; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTISM; CAUCASIAN; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY SUPPLEMENT; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; AUTISM SPECTRUM DISORDER; BEHAVIOR; BLOOD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET THERAPY; ELEMENTAL DIET; INFLAMMATION; METABOLISM; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; PSYCHOLOGY; REPRODUCIBILITY; TREATMENT OUTCOME;

AUTISM SPECTRUM DISORDER; BEHAVIORAL SYMPTOMS; CHILD; CHILD, PRESCHOOL; CORTICOTROPIN-RELEASING HORMONE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET THERAPY; FEMALE; FOOD, FORMULATED; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUTEOLIN; MALE; NEUROTENSIN; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84977763636     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.142     Document Type: Article

References (86)

1. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65: 591-598.
2. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120: 1183-1215.
3. McPartland J, Volkmar FR. Autism and related disorders. Handb Clin Neurol 2012; 106: 407-418.
4. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 2008; 9: 341-355.
5. Centers for Disease Control and Prevention. CDC estimates 1 in 68 children has been identified with autism spectrum disorder, 2014. http://wwwcdcgov/media/releases/2014/p0327-autism-spectrum-disorderhtml.
6. Hornig M, Weissenbock H, Horscroft N, Lipkin WI. An infection-based model of neurodevelopmental damage. Proc Natl Acad Sci USA 1999; 96: 12102-12107.
7. Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc Natl Acad Sci USA 2012; 109: 12776-12781.
8. Blenner S, Reddy A, Augustyn M. Diagnosis and management of autism in childhood. BMJ 2011; 343: d6238.
9. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. NeuroToxicol 2008; 29: 190-201.
10. Herbert MR Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010; 23: 103-110.
11. Rossignol DA, Genuis SJ, Frye RE. Environmental toxicants and autism spectrum disorders: a systematic review. Transl Psychiatry 2014; 4: e360.
12. Lanni KE, Schupp CW, Simon D, Corbett BA. Verbal ability, social stress, and anxiety in children with autistic disorder. Autism 2012; 16: 123-138.
13. Theoharides TC, Weinkauf C, Conti P. Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol 2004; 24: 577-581.
14. Buie T, Campbell DB, Fuchs GJ III, Furuta GT, Levy J, Vandewater J et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010; 125: S1-18.
15. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012; 17: 290-314.
16. Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M et al. Brief report: 'allergic symptoms' in children with autism spectrum disorders. More than meets the eye? J Autism Dev Disord 2011; 41: 1579-1585.
17. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006; 160: 825-830.
18. Theoharides TC, Zhang B. Neuro-Inflammation, blood-brain barrier, seizures and autism. J Neuroinflamm 2011; 8: 168.
19. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 2012; 71: 444-457.
20. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun 2014; 5: 5748.
21. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology 2014; 141: 314-327.
22. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology 1998; 139: 403-413.
23. Theoharides TC Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol 2009; 22: 859-865.
24. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis and related diseases. N Engl J Med 2015; 373: 163-172.
25. Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Theoharides A et al. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflamm 2010; 7: 48.
26. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973; 248: 6854-6861.
27. Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes. Curr Opin Endocrinol Diabetes Obes 2011; 18: 75-82.
28. Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli AA et al. Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing bull terriers with a phenotype similar to autism. Transl Psychiatry 2014; 4: e466.
29. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006; 103: 7759-7764.
30. Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. Mast cells, brain inflammation and autism. Eur J Pharmacol 2015. pii: S0014-2999(15)00398-2.
31. Kritas SK, Saggini A, Cerulli G, Caraffa A, Antinolfi P, Pantalone A et al. Corticotropin-releasing hormone, microglia and mental disorders. Int J Immunopathol Pharmacol 2014; 27: 163-167.
32. Theoharides TC Is a subtype of autism an 'allergy of the brain'? Clin Ther 2013; 35: 584-591.
33. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K et al. Mast cell activation and autism. Biochim Biophys Acta 2012; 1822: 34-41.
34. Middleton EJ, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52: 673-751.
35. Weng Z, Patel A, Panagiotidou S, Theoharidess TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 2014; 14: 1044-1052.
36. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005; 145: 934-944.
37. Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ et al. Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch Pharm Res 2008; 31: 1303-1311.
38. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000; 30: 501-508.
39. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P et al. Luteolin inhibits mast cell-mediated allergic inflammation. J Biol Regul Homeost Agents 2013; 27: 955-959.
40. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 2008; 105: 7534-7539.
41. Parker-Athill E, Luo D, Bailey A, Giunta B, Tian J, Shytle RD et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 2009; 217: 20-27.
42. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008; 155: 1076-1084.
43. Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett 2008; 448: 175-179.
44. Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007; 73: 55-63.
45. Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y et al. Luteolin triggers global changes in the microglial transcriptome leading to a unique antiinflammatory and neuroprotective phenotype. J Neuroinflamm 2010; 7: 3.
46. Jang S, Dilger RN, Johnson RW. Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J Nutr 2010; 140: 1892-1898.
47. Kao TK, Ou YC, Lin SY, Pan HC, Song PJ, Raung SL et al. Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia. J Nutr Biochem 2011; 22: 612-624.
48. Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos KD et al. Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol 2010; 23: 1015-1020.
49. Franco JL, Posser T, Missau F, Pizzolatti MG, Dos Santos AR, Souza DO et al. Structure-activity relationship of flavonoids derived from medicinal plants in preventing methylmercury-induced mitochondrial dysfunction. Environ Toxicol Pharmacol 2010; 30: 272-278.
50. Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther 2013; 35: 592-602.
51. Kempuraj D, Konstantinidou A, Boscolo P, Ferro F, Di Giannantonio M, Conti CM et al. Cytokines and the brain. Int J Immunopathol Pharmacol 2004; 17: 229-232.
52. Xu N, Li X, Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflamm 2015; 2015: 531518.
53. Tonhajzerova I, Ondrejka I, Mestanik M, Mikolka P, Hrtanek I, Mestanikova A et al. Inflammatory activity in autism spectrum disorder. Adv Exp Med Biol 2015; 861: 93-98.
54. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de WJ Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2011; 25: 40-45.
55. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011; 25: 181-213.
56. Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008; 30: 303-311.
57. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57: 67-81.
58. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009; 207: 111-116.
59. Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ. Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry 2015; 20: 440-446.
60. Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovasc Res 2003; 59: 241-249.
61. Kandere-Grzybowska K, Kempuraj D, Letourneau L, Asare A, Athanasiou A, Theoharides TC. IL-1 induces differential release of IL-6 form human mast cells. FASEB J 2002; 16: A332.
62. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de WJ Altered T cell responses in children with autism. Brain Behav Immun 2011; 25: 840-849.
63. Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007; 36: 361-365.
64. Cocchiara R, Bongiovanni A, Albeggiani G, Azzolina A, Geraci D. Evidence that brain mast cells can modulate neuroinflammatory responses by tumor necrosis factor-α production. Neuroreport 1998; 9: 95-98.
65. Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005; 33: 195-201.
66. Zhang B, Alysandratos KD, Angelidou A, Asadi S, Sismanopoulos N, Delivanis DA et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis. J Allergy Clin Immunol 2011; 127: 1522-1531.
67. Olszewski MB, Groot AJ, Dastych J, Knol EF. TNF trafficking to human mast cell granules: mature chain-dependent endocytosis. J Immunol 2007; 178: 5701-5709.
68. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci USA 2005; 102: 6467-6472.
69. Gilmore JH, Jarskog LF, Vadlamudi S. Maternal poly I: C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat. J Neuroimmunol 2005; 159: 106-112.
70. Al-Ayadhi LY, Mostafa GA. Elevated serum levels of interleukin-17 A in children with autism. J Neuroinflamm 2012; 9: 158.
71. Napolioni V, Ober-Reynolds B, Szelinger S, Corneveaux JJ, Pawlowski T, Ober-Reynolds S et al. Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder. J Neuroinflamm 2013; 10: 38.
72. Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Azcutia V et al. IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 2012; 188: 6287-6299.
73. Dudeck A, Suender CA, Kostka SL, von SE, Maurer M. Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol 2011; 41: 1883-1893.
74. Kenna TJ, Brown MA. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol 2013; 9: 375-379.
75. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 2010; 107: 2687-2692.
76. Johnson RA, Lam M, Punzo AM, Li H, Lin BR, Ye K et al. 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome. J Appl Physiol 2012; 112: 704-710.
77. Theoharides T, Athanassiou M, Panagiotidou S, Doyle R. Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders. J Neuroimmunol 2015; 279: 33-38.
78. Harwood M, nielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007; 45: 2179-2205.
79. Kawanishi S, Oikawa S, Murata M. Evaluation for safety of antioxidant chemopreventive agents. Antioxid Redox Signal 2005; 7: 1728-1739.
80. Li L, Gu L, Chen Z, Wang R, Ye J, Jiang H. Toxicity study of ethanolic extract of Chrysanthemum morifolium in rats. J Food Sci 2010; 75: T105-T109.
81. Jager AK, Saaby L. Flavonoids and the CNS. Molecules 2011; 16: 1471-1485.
82. Chen Z, Zheng S, Li L, Jiang H. Metabolism of flavonoids in human: a comprehensive review. Curr Drug Metab 2014; 15: 48-61.
83. Hollman PC, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 1997; 51: 305-310.
84. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995; 62: 1276-1282.
85. Theoharides TC, Asadi S. Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders. J Clin Psychopharmacol 2012; 32: 437-440.
86. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011; 19: 1769-1779.